- Home
- PHVS vs USPH Comparison
PHVS vs USPH Comparison
Compare PHVS & USPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- USPH
- Stock Information
- Founded
- PHVS 2015
- USPH 1990
- Country
- PHVS Switzerland
- USPH United States
- Employees
- PHVS N/A
- USPH N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- USPH Medical/Nursing Services
- Sector
- PHVS Health Care
- USPH Health Care
- Exchange
- PHVS Nasdaq
- USPH Nasdaq
- Market Cap
- PHVS 1.3B
- USPH 1.3B
- IPO Year
- PHVS 2021
- USPH 1992
- Fundamental
- Price
- PHVS $24.30
- USPH $78.99
- Analyst Decision
- PHVS Strong Buy
- USPH Strong Buy
- Analyst Count
- PHVS 5
- USPH 4
- Target Price
- PHVS $35.60
- USPH $110.25
- AVG Volume (30 Days)
- PHVS 123.2K
- USPH 117.0K
- Earning Date
- PHVS 11-12-2025
- USPH 11-04-2025
- Dividend Yield
- PHVS N/A
- USPH 2.29%
- EPS Growth
- PHVS N/A
- USPH 116.39
- EPS
- PHVS N/A
- USPH 2.29
- Revenue
- PHVS N/A
- USPH $722,201,000.00
- Revenue This Year
- PHVS N/A
- USPH $18.74
- Revenue Next Year
- PHVS N/A
- USPH $6.07
- P/E Ratio
- PHVS N/A
- USPH $34.30
- Revenue Growth
- PHVS N/A
- USPH 16.25
- 52 Week Low
- PHVS $11.51
- USPH $62.77
- 52 Week High
- PHVS $26.33
- USPH $101.20
- Technical
- Relative Strength Index (RSI)
- PHVS 59.77
- USPH 40.63
- Support Level
- PHVS $23.20
- USPH $78.18
- Resistance Level
- PHVS $24.75
- USPH $86.74
- Average True Range (ATR)
- PHVS 1.29
- USPH 2.10
- MACD
- PHVS 0.07
- USPH -0.95
- Stochastic Oscillator
- PHVS 84.81
- USPH 8.06
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About USPH U.S. Physical Therapy Inc.
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.